Regeneron (REGN) Pharmaceuticals announced updated data for their investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin, OTOF, gene were published in The New England Journal of Medicine and presented during an oral presentation at the annual American Academy of Otolaryngology-Head and Neck Surgery, AAO-HNSF, meeting. These latest results from the pivotal CHORD trial show 11 out of 12 participants have experienced clinically meaningful hearing improvements, including 3 who achieved normal hearing levels. Additionally, eight participants with longer follow-up showed stability or continued improvement in their hearing, and among three who completed speech assessments, all showed significant improvement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron and Bayer Complete Long-term Study on Retinopathy of Prematurity Treatments
- Regeneron Completes Study on Aflibercept’s Safety in Real-World Settings
- Regeneron’s Odronextamab Study Update: A Potential Game-Changer in B-Cell Malignancies
- Regeneron price target lowered to $756 from $761 at Morgan Stanley
- Alnylam and Regeneron Join Forces in Promising Alzheimer’s Study